Skip to main content

Table 3 Clinical predictors for weight loss during treatment

From: Impact of weight loss on survival after chemoradiation for locally advanced head and neck Cancer: secondary results of a randomized phase III trial (SAKK 10/94)

Weight loss during treatment

 

No weight loss

<=5% weight loss

>5-10% weight loss

>10% weight loss

p-value*

Sex = Female

7 (21.2%)

8 (24.2%)

13 (39.4%)

5 (15.2%)

0.5

Sex = Male

27 (14.4%)

65 (34.6%)

62 (33.0%)

34 (18.1%)

 

WHO performance = 0

17 (13.7%)

36 (29.0%)

43 (34.7%)

28 (22.6%)

0.1

WHO performance > = 1

17 (17.5%)

37 (38.1%)

32 (33.0%)

11 (11.3%)

 

Age < 50 years

13 (21.3%)

21 (34.4%)

18 (29.5%)

9 (14.8%)

0.4

Age > = 50 years

21 (13.1%)

52 (32.5%)

57 (35.6%)

30 (18.8%)

 

Site = Hypopharynx

10 (18.5%)

17 (31.5%)

15 (27.8%)

12 (22.2%)

0.5

Site = Other

24 (14.4%)

56 (33.5%)

60 (35.9%)

27 (16.2%)

 

T classification = cT1-2

4 (10.0%)

14 (35.0%)

15 (37.5%)

7 (17.5%)

0.8

T classification = cT3-4

30 (16.6%)

59 (32.6%)

60 (33.1%)

32 (17.7%)

 

N classification = cN0-1

14 (15.1%)

30 (32.3%)

38 (40.9%)

11 (11.8%)

0.1

N classification = cN2-3

20 (15.6%)

43 (33.6%)

37 (28.9%)

28 (21.9%)

 

Acute dysphagia = No

16 (16.7%)

38 (39.6%)

27 (28.1%)

15 (15.6%)

0.2

Acute dysphagia = Yes

18 (14.5%)

35 (28.2%)

47 (37.9%)

24 (19.4%)

 

Parenteral nutrition or feeding tube = No

24 (16.7%)

51 (35.4%)

44 (30.6%)

25 (17.4%)

0.4

Parenteral nutrition or feeding tube = Yes

9 (11.8%)

22 (28.9%)

31 (40.8%)

14 (18.4%)

 

Arm = A (chemoradiation)

20 (18.0%)

44 (39.6%)

30 (27.0%)

17 (15.3%)

0.05

Arm = B (radiation therapy alone)

14 (12.7%)

29 (26.4%)

45 (40.9%)

22 (20.0%)

 
  1. *Fisher’s Exact test.